Safety concerns emerge as radiopharmaceuticals advance in cancer trials

Radiopharmaceuticals are being hailed for their ability to deliver radiation directly to tumours, potentially sparing surrounding healthy tissue and improving cancer therapy.

However, as more candidates enter clinical testing, developers are encountering unexpected toxicities. The radioactive isotopes, while more precise, can still deposit energy in organs such as the kidneys, liver or bone marrow, leading to safety worries.

The emerging safety data is prompting companies to re‑evaluate dosing strategies and patient monitoring, tempering some of the early enthusiasm for this promising drug class.